MULTIPLE SCLEROSIS Oral laquinimod for MS-bringing the brain into focus

作者：Brueck Wolfgang; Vollmer Timothy

来源：Nature Reviews Neurology, 2013, 9(12): 664-665.

DOI：10.1038/nrneurol.2013.234

Currently approved multiple sclerosis (MS) treatments mainly target the peripheral immune system, thereby reducing relapse rates and MRI markers of inflammation. A recent phase III trial indicates that laquinimod, a new orally active immunomodulator, has a CNS-intrinsic mode of action that is independent of effects on the peripheral immune response.

• 出版日期2013-12